The Janssen Pharmaceutical Company is a subsidiary of Johnson & Johnson. Janssen researches and produces medicines to treat various diseases, such as: heart diseases, HIV, Alzheimer’s disease, and different types of cancer. With over 30,000 employees, Janssen is headquartered in Beerse, Belgium.
The company was founded in 1953, and in 1961 became a part of Johnson & Johnson. Janssen develops many drugs that help thousands of people. Unfortunately, some of those drugs have caused serious injuries in patients.
|These drugs include:|
|Invokana, a drug used to treat type 2 diabetes|
|Xarelto, a blood clot prevention medication|
|Risperdal, an antipsychotic drug used to treat schizophrenia, bipolar disorder, and other mental illnesses|
Numerous lawsuits have been filed nationwide against Janssen and Johnson & Johnson because of these side effects.
History of Janssen Pharmaceuticals
Dr. Paul Janssen was born in 1926, the son of a doctor who had established a family business. After getting his medical degree, Dr. Paul Janssen primarily focused on the importance of chemistry in medicine, and in 1953 founded Janssen Pharmaceutica N.V., a research lab based in Belgium.
In 1961, the American corporation Johnson & Johnson purchased the Janssen pharmaceutical company. Since then, the company has researched and developed over 80 medicines to treat diseases in five healthcare areas:
- Cardiovascular & Metabolism
- Infectious Diseases & Vaccines
In 2003, Dr. Paul Janssen passed away. In his honor, Johnson & Johnson created The Dr. Paul Janssen Award for Biomedical Research. The company continues to research new treatments for complex diseases to help numerous people globally. However, thousands of people have suffered severe injuries from some of the company’s most popular drugs.
Janssen’s Dangerous Drugs
While Janssen Pharmaceuticals has successfully manufactured dozens of medicines, it has failed to warn its consumers about severe side effects some of those medicines can cause. Some of the drugs that pose serious health risks include:
Invokana is a prescription medicine designed to help lower blood sugar in adults with type 2 diabetes. Invokana is manufactured by Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson. Recent studies have linked Invokana to serious side effects such as ketoacidosis and kidney injury.
On Dec 4, 2015, the U.S. Food and Drug Administration (FDA) revised the warning labels on Invokana and other medicines that treat type 2 diabetes. The FDA strengthened the warnings by including information about potential risks of developing ketoacidosis and urinary tract infections.
Xarelto is a prescription medicine that acts as a blood thinner to prevent the formation of blood clots. Xarelto is manufactured by Bayer Pharmaceuticals and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson. Many people claim suffering, severe bleeding, and internal bleeding after taking Xarelto.
The approval process for Xarelto has been called into question after reviews of the clinical trial process found systemic errors. In fact, half of the clinical trial sites for Xarelto received the most severe rating from the US Food and Drug Administration (FDA), indicating that the inspection identified objectionable conditions or practices significant enough to warrant regulatory action.
Risperdal is a drug that was marketed by Janssen Pharmaceuticals as a treatment for schizophrenia, bipolar disorder, and autism. Although the FDA approved the drug, it had a significant potential side effect of causing gynecomastia, or swelling of breast tissue, in males. Janssen Pharmaceuticals was aware of health risks, but failed to warn consumers.
Lawsuits Against Janssen Pharmaceuticals
Lawsuits against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson corporation, have been filed across the country for injuries and deaths associated with an intake of several company’s medicines. Some have stemmed from products being defectively designed, and others have arisen from Janssen’s failure to adequately warn customers of the potential risks of its products.